Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: Systematic review of randomised controlled trials

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1135-1149

  Máiz, Luis ^a   Girón, Rosa M ^b   Olveira, Casilda ^c   Quintana, Esther ^d   Lamas, Adelaida ^a   Pastor, Dolores ^e   Cantón, Rafael ^a   Mensa, Josep ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Aztreonam lysine; Colistin; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

ACTITOB; AZTREONAM LYSINE; BRAMITOB; COLISTIMETHATE; COLISTIN; PLACEBO; TOBRAMYCIN; TOBRINEB; UNCLASSIFIED DRUG;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC THERAPY; BURKHOLDERIA CEPACIA; COMPARATIVE STUDY; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPHONIA; FORCED EXPIRATORY VOLUME; HEARING IMPAIRMENT; HUMAN; LUNG FUNCTION; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; POWDER; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; AZTREONAM; CHRONIC DISEASE; COLISTIN; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOBRAMYCIN;

EID: 84877877188     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.790366     Document Type: Review

References (39)

1. Rosenstein BJ, Zeitlin PL. Cystic Fibrosis. Lancet 1998;35(9098):277-82
2. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176(10):957-69
3. Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34
4. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91-100
5. Simmonds NJ, Macneill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010;36(6):1277-83
6. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis. 3rd edition. UK Cystic Fibrosis Trust, London; 2009
7. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16(4):749-67
8. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8(5):295-315
9. Ballmann M, Smyth A, Geller DE. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Resp Med 2011;105(Suppl 2):S2-S8
10. Denyer J, Black A, Nikander K, et al. Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis. J Aerosol Med Pulm Drug Deliv 2010;23(Suppl 1):S45-54
11. Chuchalin A, Amelina E, Bianco F. Tobramycin for inhalation in cystic fibrosis: beyond respiratory improvements. Pulm Pharmacol Ther 2009;22(6):526-32
12. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135(5):1223-32
13. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178(9):921-8
14. Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011;10(4):234-42
15. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19(6):831-8
16. Day AJ, Williams J, McKeown C, et al. Evaluation of inhaled colomycin in children with cystic fibrosis [abstract]. Proceedings of the 10th International Cystic Fibrosis Congress; 5-10 March 1988; Sydney; Abstract 106
17. Ramsey BW, Pepe MS, Quan JM, et al. Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340(1):23-30
18. Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33(4):269-76
19. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38(4):314-20
20. Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007;9(Suppl 1):11-20
21. Chuchalin A, Csiszer E, Gyurkovics K, et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007;9(Suppl 1):21-31
22. Mazurek H, Lenoir G, Pelikan L, et al. Head-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (Pa) infection. J Cyst Fibros 2011;10(Suppl 1):S28
23. Mazurek H, Chiron R, Pelikan L, et al. Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups. J Cyst Fibros 2011;10(Suppl 1):S28
24. Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2010;46(3):230-8
25. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61
26. Galeva I, Konstan MW, Higgins M, et al. A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial. J Cyst Fibros 2012;11(Suppl 1):S12; Abstract WS5.6
27. Quittner AL, Higgins M, Angyalosi G, et al. Trends in health-related quality of life (HRQoL) in cystic fibrosis with tobramycin inhalation powder: the EDIT trial. J Cyst Fibros 2012;11(Suppl 1):S73
28. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013;12:130-40
29. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20(3):658-64
30. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006;5(4):261-3
31. Goldman M, Schuster A, Halliburn C, et al. A randomised, open label Phase III study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros 2012;11(Suppl 1):S12
32. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996;312(7023):71-2
33. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibrosis 2008;7(6):523-30
34. Parkins MD, Elborn JS. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respi Med 2011;5(5):609-22
35. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68:344-50
36. Assael BM. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. Expert Rev Anti Infect Ther 2011;9:967-73
37. European cystic fibrosis society patient registry. Annual Data Report. 2008-2009 Data
38. Montgomery AB, Abuan T, Yeager MA. Regulatory aspects of Phase III endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. J Aerosol Med Pulm Drug Deliv 2012;25:198-203
39. Doring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-79